2088518-51-6
2088518-51-6 structure
- Name: Rintodestrant
- Chemical Name: Rintodestrant
- CAS Number: 2088518-51-6
- Molecular Formula: C26H19FO5S
- Molecular Weight: 462.49
- Catalog: Signaling Pathways Cell Cycle/DNA Damage CDK
- Create Date: 2022-01-14 16:50:32
- Modify Date: 2024-04-11 10:54:18
-
Rintodestrant (G1T48) is an orally active, non-steroidal and selective estrogen receptor degrader. Rintodestrant (G1T48) is also a CDK4/6 inhibitor[1].
| Name | Rintodestrant |
|---|
| Description | Rintodestrant (G1T48) is an orally active, non-steroidal and selective estrogen receptor degrader. Rintodestrant (G1T48) is also a CDK4/6 inhibitor[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Rintodestrant (G1T48) is a potent and efficacious inhibitor of estrogen-mediated transcription and proliferation in ER-positive breast cancer cells, similar to the pure antiestrogen fulvestrant[1]. Rintodestrant (G1T48) selectively inhibits the growth of ER-positive, but not ER-negative, breast cancer cells[1]. Cell Viability Assay[1] Cell Line: MCF7 cells. Concentration: 1 pM-1 μM. Incubation Time: 18 h. Result: Downregulates the estrogen receptor in breast cancer cells. Significantly inhibited estrogen-mediated growth of MCF7 cells demonstrating approximately threefold higher potency when compared to Fulvestrant. Does not impact apoptosis in MCF7 breast cancer cells. |
| In Vivo | Rintodestrant (G1T48, 30 or 100 mg/kg) inhibits estrogen signaling in endocrine-resistant breast cancer models[1]. Animal Model: MCF7 xenograft tumors[1]. Dosage: 30 or 100 mg/kg. Administration: P.O. daily for 28 days. Result: Demonstrated dose-dependent inhibition of TamR tumor growth. |
| References |
| Molecular Formula | C26H19FO5S |
|---|---|
| Molecular Weight | 462.49 |